Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAA50 | Q9GZZ1 | 2/20 | 0.90 |
| ▸ | CHAT | P28329 | 2/20 | 0.84 |
| ▸ | EP300 | Q09472 | 4/20 | 0.83 |
| ▸ | KAT5 | Q92993 | 2/20 | 0.83 |
| ▸ | AURKA | O14965 | 2/20 | 0.83 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.83 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24800603 | 1.00 | NAA50 (0.90) | NAA50CHATEP300KAT5AURKA | |
| SCHEMBL13461662 | 1.00 | NAA50 (0.90) | NAA50CHATEP300KAT5AURKA | |
| SCHEMBL27888712 | 1.00 | NAA50 (0.90) | NAA50CHATEP300KAT5AURKA | |
| SCHEMBL28164093 | 1.00 | NAA50 (0.90) | NAA50CHATEP300KAT5AURKA | |
| SCHEMBL60436 | 1.00 | NAA50 (0.90) | NAA50CHATEP300KAT5AURKA | |
| SCHEMBL31690470 | 0.99 | NAA50 (0.89) | NAA50CHATEP300KAT5AURKA | |
| Acetone SCHEMBL27777287 | 0.99 | NAA50 (0.89) | NAA50CHATEP300KAT5AURKA | |
| Hydrogen Sulfide SCHEMBL25316691 | 0.99 | NAA50 (0.89) | NAA50CHATEP300KAT5AURKA | |
| Acetic Acid SCHEMBL29287784 | 0.99 | NAA50 (0.88) | NAA50CHATEP300KAT5AURKA | |
| Acetic Acid SCHEMBL31361751 | 0.99 | NAA50 (0.88) | NAA50CHATEP300KAT5AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230372411-A1 | Methods and Compositions for Treatment of Microbiome Associated Disorders | Pendulum Therapeutics, Inc. | 2023-11-23 | — | — | US | disclosed |
| US-11781120-B2 | Biosynthesis of polyketides | Gonzalez, Ramon (US) | 2023-10-10 | — | — | US | disclosed |
| US-11692207-B2 | Enzymatic methods for butanol production | NEWPEK S.A. DE C.V. (MX) | 2023-07-04 | — | — | US | disclosed |
| WO-2022266723-A1 | METHODS | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2022-12-29 | — | — | WO | disclosed |
| US-20210222209-A1 | ENZYMATIC METHODS FOR BUTANOL PRODUCTION | NEWPEK S.A. DE C.V. (MX) | 2021-07-22 | — | — | US | disclosed |
| EP-3452606-A1 | ENZYMATIC METHODS FOR BUTANOL PRODUCTION | Newpek S.A. De C.V. (MX) | 2019-03-13 | — | — | EP | disclosed |
| US-9970037-B2 | Methods and materials for making simvastatin and related compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-05-15 | — | — | US | disclosed |
| WO-2017191483-A1 | ENZYMATIC METHODS FOR BUTANOL PRODUCTION | NEWPEK S.A. DE C.V. (MX) | 2017-11-09 | — | — | WO | disclosed |
| US-9757407-B2 | Treatment of viral infections by modulation of host cell metabolic pathways | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2017-09-12 | — | — | US | disclosed |
| US-9694090-B2 | Process for preparing hyperpolarized substrates and method for MRI | BRACCO IMAGING S.P.A. (IT) | 2017-07-04 | — | — | US | disclosed |
| US-8981056-B2 | Variant LovD polypeptide | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-03-17 | — | — | US | disclosed |
| US-8951754-B2 | Methods and materials for making simvastatin and related compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-02-10 | — | — | US | disclosed |
| US-20130096420-A1 | Process For Preparing Hyperpolarized Substrates And Method For MRI | BRACCO IMAGING S.P.A. (IT) | 2013-04-18 | — | — | US | disclosed |
| US-20130065850-A1 | TREATMENT OF VIRAL INFECTIONS BY MODULATION OF HOST CELL METABOLIC PATHWAYS | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2013-03-14 | — | — | US | disclosed |
| US-20120315680-A1 | METHODS AND MATERIALS FOR MAKING SIMVASTATIN AND RELATED COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-12-13 | — | — | US | disclosed |
| US-20120276606-A1 | RECOMBINANT MICROORGANISMS WITH 1,3-BUTANEDIOL-PRODUCING FUNCTION AND USES THEREOF | DAICEL CORPORATION (JP) | 2012-11-01 | — | — | US | disclosed |
| US-8288147-B2 | Host cells for production of isoprenoid compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-10-16 | — | — | US | disclosed |
| US-20120190038-A1 | LovD MUTANTS EXHIBITING IMPROVED PROPERTIES TOWARDS SIMVASTATIN SYNTHESIS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-07-26 | — | — | US | disclosed |
| US-20110229958-A1 | Host Cells for Production of Isoprenoid Compounds | Amyris, Inc. | 2011-09-22 | — | — | US | disclosed |
| US-20090186358-A1 | Pathway Analysis of Cell Culture Phenotypes and Uses Thereof | WYETH (US) | 2009-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230372411-A1 | Methods and Compositions for Treatment of Microbiome Associated Disorders | FABP2, FADS1, ELOVL1 | NAA50 948/4885CHAT 514/4885EP300 1831/4885 |
| US-20130096420-A1 | Process For Preparing Hyperpolarized Substrates And Method For MRI | HOGA1, HAMP, GLS2 | NAA50 868/4885CHAT 1380/4885EP300 4088/4885 |
| US-20130065850-A1 | TREATMENT OF VIRAL INFECTIONS BY MODULATION OF HOST CELL METABOLIC PATHWAYS | GOT2, MAVS, ME3 | NAA50 1314/4885CHAT 2115/4885EP300 3343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.